Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: Incidence and outcome over 2 years

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 3, 1999, Pages 228-234

  Labetoulle, Marc ^a   Goujard, Cécile ^a   Frau, Eric ^a   Rogier, Hélène ^a   Niessen, Françoise ^b   Furlan, Valérie ^a   Lantz, Olivier ^a   Lecointe, Didier ^a   Delfraissy, Jean François ^a   Offret, Hervé ^a  

^a BICÊTRE HOSPITAL   (France)

^b Hôpital de Bicêtre ^*

Author keywords

CMV retinitis; Epidemiology; Eye; HIV; Protease inhibitors

Indexed keywords

PROTEINASE INHIBITOR;

ARTICLE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETINITIS; TREATMENT OUTCOME; VIRUS LOAD;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0042871263     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199911010-00003     Document Type: Article

References (44)

1. Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983;90:859-73.
2. Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985;92:472-84.
3. Jabs DA, Green WR, Fox R, Polk BF, Bartlett JG. Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology 1989;96:1092-9.
4. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996;114:821-7.
5. LeHoang P, Girard B, Rousselie F, eds. Oeil et sida. Paris: Doin, 1989.
6. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992;5:1069-74.
7. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993;115:575-82.
8. Cochereau I, Korobelnik JF, Petit E, Matheron S, Longuet P, Hoang-Xuan T. Prognosis of retinal detachment in cytomegalovirus retinitis. J Fr Ophtalmol 1995;18:603-607.
9. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
10. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
11. Mouton Y, Alfandari S, Valette M et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997;11:F101-5.
12. Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
13. Doan S, Badeion I, Chaine G. Evolution of cytomegalovirus retinitis in AIDS patients treated by triple antiretroviral combination therapy. J Fr Ophtalmol 1998;21:34-41.
14. Baril L, Jouan M, Caumes E, Mengcal X, Bricaire F, Katlama C. The impact of active antiretroviral therapy on the incidence of CMV disease in AIDS patients [abstract I31]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997.
15. Michelet C, Allavena C, Besnier J, et al. Opportunistic infections occurred under protease inhibitors in HIV patients [abstract I29]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997.
16. Binquet C, Saillour F, Bernard N, Marimoutou C, Dabis F, the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Survival of HIV-infected patients with cytomegalovirus retinitis under highly active antiretroviral therapy. AIDS 1998;12:2502-4.
17. Holland GN, Executive Committee of the American Uveitis Society. Standard diagnostic criteria for the acute retinal necrosis syndrome. Am J Ophthalmol 1994;117:663-7.
18. Engstrom RE, Jr., Holland GN, Margolis TP, et al. The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology 1994;101: 1488-1502.
19. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992;41:1-19.
20. + patients. Br J Ophthalmol 1998;82:988-90.
21. Studies on ocular complications of AIDS (SOCA) research group, in collaboration with the AIDS clinical trial group (ACTG). Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
22. Spector SA, Weingest T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993; 168:557-63.
23. LeHoang P, Girard B, Robinet M, et al. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989;96:865-73.
24. Cochereau-Massin I, LeHoang P, Lautier-Frau M et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991;98:1348-53.
25. Drew WL, Ives DV, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-20.
26. Danner SA, Matheron S. Cytomegalovirus retinitis in AIDS patients: a comparative study of intravenous and oral ganciclovir as maintenance therapy. AIDS 1996;10(Suppl 4):S7-11.
27. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. AIDS 1995;9:471-7.
28. Studies on Ocular Complications of AIDS (SOCA) Research Group, in collaboration with the AIDS Clinical Trial Group (ACTG). Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Ann Intern Med 1997;126: 264-74.
29. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997;126: 257-63.
30. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9.
31. Duker JS, Robinson M, Anand R, Ashton P. Initial experience with an eight-month sustained-release intravitreal ganciclovir implant for the treatment of CMV retinitis associated with AIDS. Ophthalmic Surg Lasers 1995;26:442-8.
32. Labetoulle M, Goujard C, Frau E, et al. Incidence and evolution of viral retinitis in HIV-infected patients treated with HIV-protease inhibitors. J Fr Ophtalmol 1998;21:567-76.
33. + counts. Arch Ophthalmol 1995;113:18
34. Baglivo E, Dosso A, Leuenberger PM. Cytomegalovirus retinitis in an AIDS patient without severe depletion in CD4 cell count. Br J Ophthalmol 1995;79:962-63.
35. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
36. Hochster H, Dieterich DT, Bozzette SA et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: an AIDS Clinical Trial Group Study. Ann Intern Med 1990;113:111-17.
37. Jacobson MA, Zegans M, Pavan PR et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5.
38. Gilquin J, Piketty C, Thomas V, Gonzales-Canali G, Kazatchkine MD. Acute CMV infection in AIDS patients receiving combination therapy including protease inhibitors [abstract 354]. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
39. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-16.
40. + repertoire during antiviral therapy. Nat Med 1998;4:215-21.
41. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
42. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998;4:953-6.
43. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anti-cytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998; 126:817-22.
44. + counts. Ophthalmology 1998;105: 1259-64.